IPP Bureau
Roche inaugurates new campus for Digital Centre of Excellence in Pune
By IPP Bureau - January 26, 2024
The new campus has been designed as an employee-centred experience and ecosystem zone
Health Minister Mandaviya inaugurates super specialty block at GSVM Medical College in UP
By IPP Bureau - January 25, 2024
Dr. Mandaviya also laid the foundation stone for an All India Institute of Speech and Hearing (AIISH) Satellite Centre in Kanpur
Shilpa Medicare directed to to pay damage to Celltrion
By IPP Bureau - January 25, 2024
The matter of Arbitration between Shilpa Medicare Limited and Celltrion towards supply and distribution agreement
Laurus Labs posts Q3 FY24 consolidated PAT at Rs. 23.14 Cr
By IPP Bureau - January 25, 2024
Laurus Labs has reported total income of Rs. 1197.35 crores during the period ended December 31, 2023
Aarti Drugs posts Q3 FY24 consolidated PAT at Rs. 36.71 Cr
By IPP Bureau - January 25, 2024
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
Lily announces positive gene therapy result for genetic hearing loss
By IPP Bureau - January 25, 2024
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
BenevolentAI appoints former Bayer R&D head Dr. Joerg Moeller as CEO
By IPP Bureau - January 25, 2024
An accomplished R&D leader and champion of the application of AI to drug discovery
ImmunoBrain Checkpoint appoints Dr. Sanjay Keswani as CEO
By IPP Bureau - January 24, 2024
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
Aster DM Healthcare gets shareholders nod to separate the GCC business
By IPP Bureau - January 24, 2024
The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years
Lupin receives tentative USFDA approval for Rivaroxaban Tablets USP
By IPP Bureau - January 24, 2024
Cipla posts Q3 FY24 consolidated PAT at Rs. 1,055.90 Cr
By IPP Bureau - January 23, 2024
Cipla has reported total income of Rs. 6,788.44 crores during the period ended December 31, 2023
Sagimet Biosciences announces positive topline results from phase 2b trial of denifanstat
By IPP Bureau - January 23, 2024
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
EMA grants ODD to GC Biopharma's treatment for Sanfilippo Syndrome
By IPP Bureau - January 23, 2024
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
European Commission grants ODD to NS-229 for treatment of Eosinophilic Granulomatosis
By IPP Bureau - January 23, 2024
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
Granules India posts Q3 FY24 consolidated PAT at Rs. 125.65 Cr
By IPP Bureau - January 23, 2024
Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023
